New therapeutic approaches in breast cancer

Maturitas

Volumn 68, Issue 2, 2011, Pages 121-128

  Davies, Eleri ^a   Hiscox, Stephen ^b  

^a SINGLETON HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; EGFR; HER2; mTOR; Targeted therapy

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ERTUMAXOMAB; ESTROGEN; EVEROLIMUS; FULVESTRANT; GEFITINIB; GELDANAMYCIN; INIPARIB; LAPATINIB; LETROZOLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PERTUZUMAB; PLACEBO; RAPAMYCIN; TAMOXIFEN; TANESPIMYCIN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER RISK; CLINICAL TRIAL; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; HUMAN; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 78651380337     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.10.012     Document Type: Review

References (71)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 2005 1687 1717
2. A. Howell The endocrine prevention of breast cancer Best Pract Res Clin Endocrinol Metab 22 4 2008 615 623
3. M. Cianfrocca, and W. Gradishar New molecular classifications of breast cancer CA Cancer J Clin 59 5 2009 303 313
4. B. Weigelt, A. Mackay, and R. A'Hern Breast cancer molecular profiling with single sample predictors: a retrospective analysis Lancet Oncol 11 4 2010 339 349
5. I. Cohen Endometrial pathologies associated with postmenopausal tamoxifen treatment Gynecol Oncol 94 2 2004 256 266
6. M. Venturini, and L. Del Mastro Safety of adjuvant aromatase inhibitor therapy Cancer Treat Rev 32 7 2006 548 556
7. B. Fisher, J. Dignam, J. Bryant, and N. Wolmark Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial J Natl Cancer Inst 93 9 2001 684 690
8. A. Buzdar, A. Howell, and J. Cuzick Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 8 2006 633 643
9. J. Gligorov, K. Pritchard, and P. Goss Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis Breast 16 Suppl. 3 2007 S1 9
10. L. Perey, R. Paridaens, and H. Hawle Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) Ann Oncol 18 1 2007 64 69
11. L. Mauriac, G. Romieu, and J. Bines Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial Breast Cancer Res Treat 117 1 2009 69 75
12. L.F. Macedo, G.J. Sabnis, O.G. Goloubeva, and A. Brodie Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model Cancer Res 68 9 2008 3516 3522
13. S.R. Johnston New strategies in estrogen receptor-positive breast cancer Clin Cancer Res 16 7 2010 1979 1987
14. R.I. Nicholson, and S.R. Johnston Endocrine therapy - current benefits and limitations Breast Cancer Res Treat 93 Suppl. 1 2005 S3 10
15. A. Howell, N.J. Bundred, J. Cuzick, D.C. Allred, and R. Clarke Response and resistance to the endocrine prevention of breast cancer Adv Exp Med Biol 617 2008 201 211
16. J. Shou, S. Massarweh, and C.K. Osborne Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 12 2004 926 935
17. A.S. Oh, L.A. Lorant, J.N. Holloway, D.L. Miller, F.G. Kern, and D. El-Ashry Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells Mol Endocrinol 15 8 2001 1344 1359
18. S. Massarweh, C.K. Osborne, and C.J. Creighton Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function Cancer Res 68 3 2008 826 833
19. J.M. Gee, M.E. Harper, and I.R. Hutcheson The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro Endocrinology 144 11 2003 5105 5117
20. C.L. Arteaga, and C.I. Truica Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer Semin Oncol 31 Suppl. 3 2004 3 8
21. M. Cristofanilli, V. Valero, and A. Mangalik Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer Clin Cancer Res 16 6 2010 1904 1914
22. I.E. Smith, G. Walsh, and A. Skene A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer J Clin Oncol 25 25 2007 3816 3822
23. E. Gutteridge, A. Agrawal, R. Nicholson, K. Leung Cheung, J. Robertson, and J. Gee The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study Int J Cancer 126 8 2010 1806 1816
24. M.D. Green, P.A. Francis, and V. Gebski Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer Ann Oncol 20 11 2009 1813 1817
25. M. Guix, M. Granja Nde, and I. Meszoely Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers J Clin Oncol 26 6 2008 897 906
26. M.N. Dickler, M.A. Cobleigh, K.D. Miller, P.M. Klein, and E.P. Winer Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Breast Cancer Res Treat 115 1 2009 115 121
27. M.N. Dickler, H.S. Rugo, and C.A. Eberle A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer Clin Cancer Res 14 23 2008 7878 7883
28. J.A. McCubrey, L.S. Steelman, and W.H. Chappell Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim Biophys Acta 1773 8 2007 1263 1284
29. S. Miyakis, G. Sourvinos, and D.A. Spandidos Differential expression and mutation of the ras family genes in human breast cancer Biochem Biophys Res Commun 251 2 1998 609 612
30. G.J. Clark, and C.J. Der Aberrant function of the ras signal transduction pathway in human breast cancer Breast Cancer Res Treat 35 1 1995 133 144
31. S. Malaney, and R.J. Daly The ras signaling pathway in mammary tumorigenesis and metastasis J Mammary Gland Biol Neoplasia 6 1 2001 101 113
32. S. Grant, L. Qiao, and P. Dent Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival Front Biosci 7 2002 d376 d389
33. J. Downward Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 1 2003 11 22
34. S.R.D. Johnston, T. Hickish, and P. Ellis Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer J Clin Oncol 21 13 2003 2492 2499
35. L.A Martin, J.E. Head, and S. Pancholi The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 9 2007 2458 2467
36. F. Dalenc, S.F. Doisneau-Sixou, and B.C. Allal Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis Clin Cancer Res 16 4 2010 1264 1271
37. S.R. Johnston, V.F. Semiglazov, and G.M. Manikhas A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy Breast Cancer Res Treat 110 2 2008 327 335
38. G. Liu, C.H. Marrinan, and S.A. Taylor Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336) Anticancer Drugs 18 8 2007 923 931
39. J. Gligorov, D. Azria, M. Namer, D. Khayat, and J.P. Spano Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives Crit Rev Oncol Hematol 64 2 2007 115 128
40. S. Chan, M.E. Scheulen, and S. Johnston Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23 23 2005 5314 5322
41. G. Valabrega, F. Montemurro, and M. Aglietta Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 6 2007 977 984
42. W. Xia, R.J. Mullin, and B.R. Keith Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 41 2002 6255 6263
43. I. Bauerfeind, D. Elling, and V. Heinemann Lapatinib in the treatment of hormone receptor-positive/ErbB2-positive breast cancer Breast Care (Basel) 5 s1 2010 13 15
44. M. Scaltriti, S. Chandarlapaty, and L. Prudkin Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor Clin Cancer Res 16 9 2010 2688 2695
45. J. Bischoff, and A. Ignatov The role of targeted agents in the treatment of metastatic breast cancer Breast Care (Basel) 5 3 2010 134 141
46. K. Berns, H.M. Horlings, and B.T. Hennessy A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 4 2007 395 402
47. V. Serra, B. Markman, and M. Scaltriti NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Research 2008 8022 8030
48. J. Baselga Treatment of HER2-overexpressing breast cancer Ann Oncol 21 Suppl. 7 2010 vii36 vii40
49. S. Di Cosimo, and J. Baselga Targeted therapies in breast cancer: where are we now? Eur J Cancer 44 18 2008 2781 2790
50. S. Modi, A.T. Stopeck, and M.S. Gordon Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol 25 34 2007 5410 5417
51. K.L. Jones, and A.U. Buzdar Evolving novel anti-HER2 strategies Lancet Oncol 10 12 2009 1179 1187
52. G. Brockhoff, B. Heckel, and E. Schmidt-Bruecken Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation Cell Prolif 40 4 2007 488 507
53. S.K. Pal, and M. Pegram Targeting HER2 Epitopes Semin Oncol 33 4 2006 386 391
54. J. Baselga, K.A. Gelmon, and S. Verma Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 7 2010 1138 1144
55. J. Baselga, D. Tripathy, and J. Mendelsohn Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer Semin Oncol 26 4 Suppl. 12 1999 78 83
56. P. Kiewe, S. Hasmuller, and S. Kahlert Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer Clin Cancer Res 12 10 2006 3085 3091
57. M. Jager, A. Schoberth, P. Ruf, J. Hess, and H. Lindhofer The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2 Cancer Res 69 10 2009 4270 4276
58. P. Kiewe, and E. Thiel Ertumaxomab: a trifunctional antibody for breast cancer treatment Expert Opin Investig Drugs 17 10 2008 1553 1558
59. I.E. Krop, M. Beeram, and S. Modi Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J Clin Oncol 28 16 2010 2698 2704
60. C.K. Anders, and L.A. Carey Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer Clin Breast Cancer 9 Suppl. 2 2009 S73 81
61. F.C. Bidard, R. Conforti, T. Boulet, S. Michiels, S. Delaloge, and F. Andre Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers Ann Oncol 18 7 2007 1285 1286
62. M.D. Seal, and S.K. Chia What is the difference between triple-negative and basal breast cancers? Cancer J 16 1 2010 12 16
63. R. Rouzier, C.M. Perou, and W.F. Symmans Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 2005 5678 5685
64. C. Liedtke, C. Mazouni, and K.R. Hess Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 8 2008 1275 1281
65. K. Hastak, E. Alli, and J.M. Ford Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin Cancer Res 70 20 2010 7970 7980
66. H. Liang, A.R. Tan, and Iniparib a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer IDrugs 13 9 2010 646 656
67. N. Berrada, S. Delaloge, and F. Andre Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol 21 Suppl. 7 2010 vii30 vii35
68. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2007 2666 2676
69. S.W. Wong, K.H. Tiong, and W.Y. Kong Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73 Breast Cancer Res Treat 2010
70. R.S. Finn, J. Dering, and C. Ginther Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 105 3 2007 319 326
71. S.K. Pal, and J. Mortimer Triple-negative breast cancer: novel therapies and new directions Maturitas 63 4 2009 269 274